Skip to main content
Fig. 1 | Molecular Autism

Fig. 1

From: Clinical trial of insulin-like growth factor-1 in Phelan-McDermid syndrome

Fig. 1

Significant outcome measures between baseline and week 12 of drug (IGF-1) or placebo. Mean changes are shown across the second study (left), first study [9] (center) and the combined effect (right) for the following significant outcome scores testing for time × treatment interactions: A ABC-SW, significant effect in the first study only (p = 0.04); B RBS-R Restricted Behavior, significant effect in the first study (p = 0.04) and combined study effect (p = 0.03); C SP Under-responsive/seeks sensation, significant effect in the second study only (p = 0.03); and D SP Modulation of body movement and position, significant effect in the second study only (p = 0.02). E Exploratory analysis applying a Mann Whitney-U test on difference in scores at 12 weeks identified significant reduction in ABC-hyperactivity scores in the first (p = 0.03) and combined study effect (p = 0.01). Mean differences and standard errors are shown for all outcome measures. Abbreviations: ABC-SW = Aberrant Behavior Checklist—Social Withdrawal subscale; RBS = Repetitive Behavior Scale; SP = Sensory Profile; ABC-hyperactivity = Aberrant Behavior Checklist-hyperactivity

Back to article page